Compare Organon & Co. Common Stock (OGN) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ishares Msci Thailand Etf — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ishares Msci Thailand Etf trades at $71.15 (market cap $424.09M). The key difference: Organon & Co. Common Stock is far larger — about 8.5× Ishares Msci Thailand Etf's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Ishares Msci Thailand Etf pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ishares Msci Thailand Etf for 67 Days on average.
| OGN | THD | |
|---|---|---|
Market Cap | $3.62B | $424.09M |
Volume | 2,892,999 | 1,217,048 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $75.06 |
52-Week Low | $5.70 | $57.86 |
Typical Hold Time | 0 Days | 67 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
THD (iShares MSCI Thailand ETF) trades at $71.17, down 0.27% with bearish technical signals across moving averages and oscillators. Short interest surged 90.6% in September 2026 (Defense World, 2026-10-01), indicating rising bearish sentiment. The ETF has delivered strong 38% returns over the past year (Seeking Alpha, 2026-07-09) but faces headwinds from capital rotation away from Asian AI-related markets.
Outlook remains cautious given technical weakness and elevated short positioning. Investment opportunity exists for exposure to Thailand's AI hardware plays like Delta Electronics, but vulnerability to profit-taking and regional capital outflows presents significant near-term risks for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
